Biologists have engineered adeno-associated viruses that are better at capsid filling, potentially resulting in higher productivity.
The efficacy of adeno-associated virus (AAV)-mediated gene therapy for the inner ear is fundamentally constrained by the natural tropism of viral ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
From a virus's point of view, invading our cells is a matter of survival. The virus makes a living by highjacking cellular processes to produce more of the proteins that make it up. From our point of ...
Viral vectors and vaccines navigate public distrust while advancing through AI design, COVID response lessons, and promising ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results